Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support

Prostate

Volumn 43, Issue 3, 2000, Pages 215-222

  Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgen blockade; Early diagnosis; Early treatment; Prostate cancer; Screening; Survival

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANADA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0034066457     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000515)43:3<215::AID-PROS7>3.0.CO;2-G     Document Type: Article

References (74)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostat Dis 1999;2:4-8.
3. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond J, Fazekas AT, Raynaud JP, Husson JM. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982;5:267-275.
4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
5. Denis L, Carnelro de Moura JL, Bono A, Sylvester R, Whelan R, Newling D, De Pauw M. Goserelin acetate and flutamide vs. bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42:119-129.
6. Dijkman GA, Janknegt RA, Dereijke TM, Debruyne FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160-163.
7. Labrie F. Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, volume 13. Philadelphia: Lippincott-Raven; 1999. p 1-9.
8. Kolata G. Prostate cancer consensus hampered by lack of data. Science 1987;236:1626-1627.
9. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
10. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997;15: 1013-1021.
11. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235-246.
12. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Lévesque J, Diamond P, Bélanger A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38:83-91.
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
14. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
15. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer. J. Urol. 1992;147:846-851.
16. Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, Diamond P, Emond J, Lemay M, Têtu B. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen. Clin Invest Med 1993; 16:425-439.
17. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
18. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, Oesterling JE. Clinical stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology 1993;41:3-8.
19. Brawer MK, Lange PH. Adjuvant therapy after radical prostatectomy. Prob Urol 1990;4:461-472.
20. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-845.
21. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-217.
22. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
23. Sheldon CA, Williams RD, Fraley EE. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol 1980;124:626-631.
24. Bostwick DG. Anatomy of the prostate: histopathology of cancer and BPH. In: 7th International Symposium: transrectal ultrasound in the diagnosis and management of BPH and prostate cancer. Chicago: American Institute of Ultrasound and Medicine; 1992. p 1-13.
25. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-294.
26. Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995; 154:460-465.
27. Hugosson J, Aus G, Bergdahl C, Bergdahl S. Prostate cancer mortality in patients surviving more than 10 years after diagnosis. J Urol 1995;154:2115-2117.
28. Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup. J Urol 1999;161:505-508.
29. Brasso K, Friis S, Juel K, Jorgensen T, Iversen P. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. J Urol 1999;161:524-528.
30. Aus G, Bergdahl S, Hugosson J, Lodding P, Norlén L. Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate-specific antigen. Scand J Urol Nephrol 1994; 28:379-384.
31. Krongrad A, Lai H, Lamm SH, Lai S. Mortality in prostate cancer. J Urol 1996;156:1084-1091.
32. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-910.
33. Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999;161:529-533.
34. Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst 1996;88:1706-1707.
35. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer 1998;82:1197-1207.
36. Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999;161: 1189-1191.
37. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267:2191-2196.
38. Whitmore WF Jr, Warner JA, Thompson IM. Expectant management of localized prostatic cancer. Cancer 1991;67:1091-1096.
39. Goodman CM, Busuttil A, Chisholm GD. Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol 1988;62:576-580.
40. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localized prostatic carcinoma. Br J Urol 1992;69:183-187.
41. Jones GW. Prospective, conservative management of localized prostate cancer. Cancer 1992;70:307-310.
42. Orestano F. Problems of wait-and-see policy in incidental carcinoma of the prostate. In: Altwein F, Schneider W, editors. Incidental carcinoma of the prostate. Berlin-Heidelberg: Springer Verlag; 1991. p 162-166.
43. Moskovitz B, Nitecki S, Richter-Levin D. Cancer of the prostate: is there a need for aggressive treatment? Urol Int 1987;42:49-52.
44. Larsson A, Norlén BJ. Five-year follow-up of patients with localized prostatic carcinoma initially referred for expectant treatment. Scand J Urol Nephrol 1985;19:30.
45. Chodak GW, Thisted RA, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
46. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retick AB, Stamey TA, Vaughan ED Jr, editors. Cambell's urology. Philadelphia: W.B. Saunders Co.; 1992. p 1200-1201.
47. Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Experimental oncogene induced prostate cancer. Cancer Surv 1991;11:55-71.
48. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
49. George NJ. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1988;I:494-497.
50. Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol 1986;136:837-839.
51. Blute ML, Zincke H, Farrow GM. Long-term follow-up of young patients with stage A adenocarcinoma of the prostate. J Urol 1986;136:840-843.
52. McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969;23:24-34.
53. Aprikian AG, Zhang ZF, Fair WR. Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients. Cancer 1994;74:1768-1777.
54. Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 1981;125:516-520.
55. Zhang G, Wasserman NF, Sidi AA, Reinberg Y, Reddy PK. Long-term followup results after expectant management of stage Al prostatic cancer. J Urol 1991;146:99-102.
56. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre FA, Lemay A, Ranaud JP. Antifertility effects of LHRH agonists in the male. J Androl 1980;1:209-228.
57. Labrie F, Bélanger A, Cusan L, Simard J, Luu-The V, Labrie C, Gomez JL, Diamond P, Candas B. History of LHRH agonist and combination therapy in prostate cancer. Endocr Rel Cancer 1996;3:243-278.
58. Denis LJ, Keuppens F, Smith PH, Whelan P, Carneiro de Moura JL, Newling D, Bono A, Sylvester R. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol 1998;33:144-151.
59. Labrie F, Cusan L, Gomez JL, Diamond P, Bélanger A. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol Urol 1997;1:253-261.
60. Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 1989;170:609-615.
61. Laverdiere J, Gomez JL, Cusan L, Suburu R, Diamond P, Lemay M, Candas B, Fortin A, Labrie F. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-252.
62. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, Candas B. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44:29-37.
63. Pilepich MV, Krall JM, Al-Saffaf M, John MJ, Dogget RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-623.
64. American Cancer Society. Guidelines for the cancer-related checkup: an update. Atlanta: American Cancer Society; 1993.
65. American Urological Association. Executive Committee report. Baltimore: American Urological Association; 1992.
66. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, Mettlin C. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982;127:928-934.
67. Schmidt JD, Mettlin CJ, Natarajan N, Peace BB, Beart RW Jr, Winchester DP, Murphy GP. Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol 1986;136:416-421.
68. Hugosson J, Aus G. Natural evolution of prostate cancer. Endocr Rel Cancer 1996;3:147-155.
69. Brown ML, Fintor L, Newman-Horm PA. The economic burden of cancer. J Natl Cancer Inst 1993;85:351-353.
70. Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Emond J, Candas B. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993;16:499-509.
71. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R, Babaian R. Cost-effective prostate-cancer detection. Reduction of low-field biopsies. Cancer 1994;74:3146-3158.
72. Hillner BE, McLeod DG, Crawford ED, Bennett CL. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995;45:633-640.
73. Labrie F. Intracrinology and cancer therapy. Sci Watch 1994;5: 3-8.
74. Labrie F, Cusan L, Gomez JL, Diamond P, Candas B. Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J Clin Endocrinol Metab 1995;80:2002-2013.